Bausch And Lomb's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bausch And Lomb (BLCO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bausch And Lomb vs Its Competitors
- TTM: Trailing 12-month revenue of 5,324M vs 108,908M combined for tracked competitors (4.7% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+4.7% annualized vs trailing 12 months), vs accelerating (+3.2%) for its tracked peer group.
- Growth: Bausch And Lomb generated 9.1% revenue growth year over year in Q2 2026, vs 6.6% for its tracked competitors combined.
- Profitability: Its -0.7% net margin compares with 21.8% for the peer group.
- Scale: Bausch And Lomb ranks #28 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.5% of industry market cap.
- Peer revenue share: Bausch And Lomb accounted for 4.7% of combined revenue among its tracked peer group, up from 4.6% a year earlier.
- Peer differentiation: Revenue per employee of $0.41M compares with $0.62M for the peer group (0.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BLCO Sales vs. its Competitors, Q2 2026
Bausch And Lomb reported revenue growth of 9.08 % year on year in Q2 2026, above its competitors' combined revenue growth of 6.60 %.
With a net margin of -0.72 %, Bausch And Lomb reported lower profitability than its competitors (21.75 %).
Bausch And Lomb generated 4.73 % of the combined sales of its peer group, up from 4.63 % a year earlier.
Bausch And Lomb vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Bausch And Lomb and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Bausch and Lomb Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Bausch And Lomb's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 9.1% for Bausch And Lomb. Bausch And Lomb's share of combined industry revenue moved from 1.26% to 1.19%, a loss of 0.06 percentage points.
Bausch And Lomb's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bausch and Lomb Corp | No | Yes | No | No |
| Competitors combined (13) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 37.50 % (3 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BLCO Stock Performance relative to its Competitors
BLCO Stock Performance relative to High-Confidence Competitors
BLCO Stock Performance relative to Similar-Size Competitors
BLCO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Johnson and Johnson | 282.9% | Outperformed |
| 2 | West Pharmaceutical Services Inc | 282.9% | Outperformed |
| 3 | Novartis Ag | 282.9% | Outperformed |
| 4 | Masimo Corp | 282.9% | Outperformed |
| 5 | Warby Parker Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bausch And Lomb's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Bausch And Lomb's Comment on Competition and Industry Peers
Publicly Traded Peers of Bausch and Lomb Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Bausch and Lomb Corp | 6,024.28 | 5,324.00 |
| Johnson and Johnson | 662,243.14 | 97,929.00 |
| Novartis Ag | 284,237.45 | 56,674.00 |
| Alcon inc | 32,416.75 | 10,401.00 |
| West Pharmaceutical Services Inc | 26,626.51 | 3,326.90 |
| The Cooper Companies Inc | 10,886.49 | 4,236.60 |
| SUBTOTAL | 1,037,994.63 | 182,864.09 |
Sign in to see all competitors of Bausch and Lomb Corp.
Sources: Bausch and Lomb Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bausch and Lomb Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bausch And Lomb's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Lenz Therapeutics Inc | Named by the company | 85% |
| Bausch Health Companies Inc | Named by the company | 85% |
| Skye Bioscience Inc | Named by the company | 85% |
| Oculis Holding Ag | Named by the company | 85% |
| Escalon Medical Corp | Named by the company | 85% |
| Staar Surgical Co | Named by the company | 85% |
| Spyglass Pharma Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Bausch And Lomb's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Bausch And Lomb's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Bausch and Lomb Corp | Vision Care 56.24 % |
| Johnson and Johnson | Oncology 29.26 % |
| West Pharmaceutical Services Inc | Proprietary Products 82.84 % |
| The Cooper Companies Inc | CooperVision 67.93 % |
| Masimo Corp | Health Care 99.95 % |
| National Vision Holdings Inc | Owned And Host Store Brands 99.16 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Bausch and Lomb Corp.
Bausch And Lomb's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bausch and Lomb Corp | 6,024 | 409,538 | -12,538 |
| Johnson and Johnson | 662,243 | 695,518 | 149,411 |
| Novartis Ag | 284,237 | 752,973 | 185,566 |
| Alcon inc | 32,417 | 416,040 | 39,200 |
| West Pharmaceutical Services Inc | 26,627 | 308,046 | 52,306 |
| The Cooper Companies Inc | 10,886 | 282,440 | 38,020 |
| PEERS TOTAL | 1,031,970 | 617,014 | 129,062 |
Sign in to see all peers for Bausch and Lomb Corp.
Bausch And Lomb's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
| The Cooper Companies Inc | United States 50.22 % |
| Staar Surgical Co | Geographic Distribution Foreign 50.73 % |
| Femasys Inc | US 97.83 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Bausch And Lomb's Position in Industry Market Structure
Market-capitalization share and concentration across all 222 companies in Bausch And Lomb's industry classification, broader than the peer set above. Market cap in millions of $.Bausch And Lomb ranks #28 of 222 companies by market capitalization in its industry, holding 0.54 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 589, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 148,204 | 13.47 % |
| 2 | Medtronic Plc | 115,016 | 10.45 % |
| 3 | Stryker Corp | 106,270 | 9.66 % |
| 4 | 3m Company | 88,536 | 8.05 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Dexcom Inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Alcon inc | 1,234 | 5.2% |
| 28 | Bausch and Lomb Corp | 5,919 | 0.54 % |
Market cap and industry share for the rest of Bausch And Lomb's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-06-26.
Bausch And Lomb's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 23 | Globus Medical Inc | 10,274 | 35.39 % |
| 24 | Henry Schein Inc | 9,836 | 31.12 % |
| 25 | Glaukos Corp | 9,326 | 89.12 % |
| 26 | Insulet Corporation | 9,238 | -59.29 % |
| 27 | Msa Safety Inc | 1,234 | 12.3% |
| 28 | Bausch and Lomb Corp | 5,919 | 36.20 % |
| 29 | Stevanato Group S p a | 1,234 | 12.3% |
| 30 | Teleflex Incorporated | 1,234 | 12.3% |
| 31 | Merit Medical Systems Inc | 1,234 | 12.3% |
| 32 | Marizyme Inc | 1,234 | 12.3% |
| 33 | Haemonetics Corporation | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Bausch And Lomb's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Bausch And Lomb's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (288 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 60.71 % | 53.35 % (avg) | +7.4 pp |
| Operating Margin | 4.40 % | industry median | +12.9 pp |
| EBITDA Margin | 12.58 % | -6.82 % (avg) | +19.4 pp |
| Capital Intensity (Capex / Revenue) | 6.51 % | 5.43 % (avg) | +1.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Bausch And Lomb's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (288 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 34.6x | - |
| EV / EBITDA | 12.4x | 19.7x | -7.3x |
| P/B | 0.9x | 4.7x | -3.8x |
| Return on Equity | -3.25 % | industry aggregate | -11.54 % |
| Return on Invested Capital | 1.23 % | -2.32 % (avg) | 3.55 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bausch And Lomb's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | 10.03 % | 15.56 % | 6.47 % |
| Operating Margin | 5.49 % | 3.14 % | 3.38 % | 2.22 % |
| Return on Invested Capital | 1.23 % | 0.73 % | 0.88 % | 0.61 % |
| P/E | 903.3x | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bausch And Lomb's Strategic Group Map
Every company in Bausch And Lomb's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Bausch And Lomb is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Bausch And Lomb's BCG Growth-Share Matrix
Relative market share (vs Bausch And Lomb's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Bausch And Lomb falls in the Dog quadrant: relative market share of 0.04x vs its largest competitor, in an industry growing revenue 9.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Bausch And Lomb's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 589 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 6.51 % vs industry average 5.43 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Bausch And Lomb's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Bausch And Lomb's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Bausch And Lomb's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Bausch And Lomb falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bausch And Lomb's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 12.9 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+4.7% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 11.5 points below the industry aggregate.
- Low relative market share vs the industry leader (0.04x).
Opportunities
No rule matched.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Bausch And Lomb's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bausch and Lomb Corp | 0.18 | 1.53 | 0.39 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Alcon inc | 0.50 | 2.12 | 0.19 |
| West Pharmaceutical Services Inc | 0.91 | 2.85 | 0.07 |
| The Cooper Companies Inc | 0.09 | 1.49 | 0.30 |
Sign in to see all peers for Bausch and Lomb Corp.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bausch And Lomb's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bausch and Lomb Corp | Q2 2026 | +9.1 % | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Alcon inc | Q4 2025 | +4.9 % | -3.7 % |
| West Pharmaceutical Services Inc | Q2 2026 | +13.9 % | +16.8 % |
| The Cooper Companies Inc | Q2 2026 | +0.6 % | +340.3 % |
| PEERS TOTAL | +8.2 % | +14.4 % |
Sign in to see all peers for Bausch and Lomb Corp.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bausch And Lomb's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bausch and Lomb Corp | Q2 2026 | - | -20.2 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Alcon inc | Q4 2025 | +6.1 % | +14.8 % |
| West Pharmaceutical Services Inc | Q2 2026 | +10.4 % | -42.6 % |
| The Cooper Companies Inc | Q2 2026 | -3.7 % | -29.1 % |
Sign in to see all peers for Bausch and Lomb Corp.
Bausch And Lomb's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bausch and Lomb Corp | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Alcon inc | 3.11% | 3.47% | 4.45% |
| West Pharmaceutical Services Inc | 13.64% | 15.29% | 18.51% |
| The Cooper Companies Inc | 4.57% | 5.09% | 6.90% |
Sign in to see all peers for Bausch and Lomb Corp.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bausch And Lomb's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bausch and Lomb Corp | - | 1.13 |
| Johnson and Johnson | 31.41 | 6.76 |
| Novartis Ag | 20.33 | 5.02 |
| Alcon inc | 32.99 | 3.12 |
| West Pharmaceutical Services Inc | 47.82 | 8.00 |
| The Cooper Companies Inc | 19.28 | 2.57 |
| PEERS AVERAGE | 28.07 | 5.68 |
Sign in to see all peers for Bausch and Lomb Corp.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.